MAP2K7 and breast carcinoma: MEK inhibitor CI-1040 (PD184352) exhibited notable antitumor activity in preclinical models, specifically against pancreatic, colon, and breast cancers, and was well tolerated in Phase I clinical trials [73] but had insufficient efficacy in Phase II clinical studies [74].